Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.

By Jordi Bruix1 , 2, T. Takayama, V. Mazzaferro, G. Chau, Jiamei Yang, M. Kudo, J. Cai, R. Poon, K. Han, W. Tak and 10 more. The Lancet Oncology, 2015

937 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Surgery

View Paper: https://www.semanticscholar.org/paper/61de729d7e22ca56ebbf07821f3a407cc55d845a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. L. Kulik
2. R. Finn
3. Andrew X. Zhu
4. Michael M. Abecassis
5. Claude B. Sirlin
6. J. Heimbach
7. Jorge Marrero
8. María E. Reig1 , 2

In Hepatology

1. L. Kulik
2. Andrew X. Zhu
3. R. Finn
4. María E. Reig1 , 2
5. Lewis R. Roberts
6. Michael M. Abecassis
7. J. Heimbach
8. Claude B. Sirlin

In Surgery

1. Jordi Bruix1 , 2

Citations in the corpus

• AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023, neutral): “[201] The open-label phase III RCT comparing atezolizumab plus bevacizumab versus active surveillance (IMbrave 050) in the adjuvant setting for HCC patients at high-risk of recurrence after resection or local ablation was the first to demonstrate positive results.”
• Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update (2017, neutral): “[208] assessed the efficacy and safety of sorafenib versus placebo as adjuvant therapy in patients with HCC after surgical resection or local ablation.”
• Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases (2019, methodology): “A randomized phase III study compared sorafenib (n = 556 patients) to placebo (n = 558) with the aim of recurrence-free survival (RFS) in patients who had a complete response after resection or thermal ablation.(117) There was no difference in the median RFS among the two groups (33.”
• Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases (2018, methodology): “A randomized phase III study compared sorafenib (n = 556 patients) to placebo (n = 558) with the aim of recurrence-free survival (RFS) in patients who had a complete response after resection or thermal ablation.(117) There was no difference in the median RFS among the two groups (33.”
• Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. (2016, methodology): “6% according to investigator assessment in STORM [14].”